Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases.
Systemic inflammatory rheumatic diseases are considered as autoimmune diseases, meaning that the balance between recognition of pathogens and avoidance of self-attack is impaired and the immune system attacks and destroys its own healthy tissue. Treatment with conventional Disease Modifying Antirheumatic Drugs (DMARDs) and/or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is often associated with various adverse reactions due to unspecific and toxic properties of those drugs. Although biologic drugs have largely improved the outcome in many patients, such drugs still pose significant problems and fail to provide a solution to all patients. Therefore, development of more effective treatments and improvements in early diagnosis of rheumatic diseases are badly needed in order to increase patient's functioning and quality of life. The reversible nature of epigenetic mechanisms offers a new class of drugs that modulate the immune system and inflammation. In fact, epigenetic drugs are already in use in some types of cancer or cardiovascular diseases. Therefore, epigenetic-based therapeutics that control autoimmunity and chronic inflammatory process have broad implications for the pathogenesis, diagnosis, and management of rheumatic diseases. This review summarises the latest information about potential therapeutic application of epigenetic modification in targeting immune abnormalities and inflammation of rheumatic diseases.
National Institute of Geriatrics Rheumatology and Rehabilitation, Department of Pathophysiology and Immunology, Warsaw, Poland.
Marzena
0000-0002-0961-6130
M
Ciechomska
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK.
Steven
S
O'Reilly
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015551:Autoimmunity / Q000235:genetics / Q000502:physiology; D044127:Epigenesis, Genetic / Q000235:genetics* / Q000502:physiology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000235:genetics / Q000628:therapy; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents